Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MIRA Pharmaceuticals, Inc. - Common Stock (NQ:MIRA)

1.320 +0.010 (+0.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 46,739,881
Open 1.330
Bid (Size) 2.230 (2)
Ask (Size) 2.250 (5)
Prev. Close 1.310
Today's Range 1.300 - 1.345
52wk Range 0.7300 - 2.560
Shares Outstanding 19,069,315
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Wednesday's after hours session: top gainers and losers
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill

Performance

YTD
+14.8%
+14.8%
1 Month
-4.3%
-4.3%
3 Month
-29.4%
-29.4%
6 Month
+23.4%
+23.4%
1 Year
+25.7%
+25.7%

More News

Read More
MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction
Via ACCESS Newswire
MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog
Via ACCESS Newswire
MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals
Via ACCESS Newswire
Monday's after hours session: top gainers and losers
Via Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation
Via ACCESS Newswire
MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage
Via ACCESS Newswire
MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin
Via ACCESS Newswire
MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study
Via ACCESS Newswire
MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain
Via ACCESS Newswire
MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition
Via ACCESS Newswire
Unusual volume stocks in Monday's session
Via Chartmill
Which stocks have an unusual volume on Thursday?
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks
Via ACCESS Newswire
US Stocks Likely To Open Higher As Trump Announces Vietnam Trade Deal: S&P 500's Golden Cross 'Reason To Expect Better Than Average Returns,' Says Expert
Via Benzinga
Topics Government Stocks
Why Datadog Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
MIRA Pharmaceuticals' Marijuana Analog Mira-55 Shows Potent Pain Relief In Preclinical Study, Stock Jumps 50% After Hours
Via Benzinga
Topics Cannabis
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Get insights into the top gainers and losers of Wednesday's after-hours session.
Via Chartmill
MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition
Via ACCESS Newswire
EXCLUSIVE: MIRA Pharmaceuticals' Soon To Be Acquired Weight Loss Drug Reverses Obesity Markers And Cuts Nicotine Craving In Animal Study
Via Benzinga
MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects
Via ACCESS Newswire

Frequently Asked Questions

Is MIRA Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, MIRA Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does MIRA Pharmaceuticals, Inc. - Common Stock trade on?
MIRA Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MIRA Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for MIRA Pharmaceuticals, Inc. - Common Stock is MIRA on the Nasdaq Stock Market
What is the current price of MIRA Pharmaceuticals, Inc. - Common Stock?
The current price of MIRA Pharmaceuticals, Inc. - Common Stock is 1.320
When was MIRA Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of MIRA Pharmaceuticals, Inc. - Common Stock was at 10/15/25 04:00 PM ET
What is the market capitalization of MIRA Pharmaceuticals, Inc. - Common Stock?
The market capitalization of MIRA Pharmaceuticals, Inc. - Common Stock is 25.17M
How many shares of MIRA Pharmaceuticals, Inc. - Common Stock are outstanding?
MIRA Pharmaceuticals, Inc. - Common Stock has 25M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.